Hereditary angioedema presenting in late middle age after angiotensin-converting enzyme inhibitor treatment

Annals of Allergy, Asthma and Immunology

Volumn 98, Issue 4, 2007, Pages 397-401

  Ricketti, Anthony J ^a,b   Cleri, Dennis J ^a,b   Ramos Bonner, Luz S ^b   Vernaleo, John R ^c  

^a ST FRANCIS MEDICAL CENTER   (United States)

^b SETON HALL UNIVERSITY   (United States)

^c WYCKOFF HEIGHTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; EZETIMIBE; LANSOPRAZOLE; LISINOPRIL; PREDNISONE; SIMVASTATIN; VALDECOXIB;

ADULT; ALLERGY TEST; ANAMNESIS; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; COMPLEMENT BLOOD LEVEL; COMPLEMENT HEMOLYSIS TEST; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 34147216739     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60889-7     Document Type: Article

References (51)

1. 1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine. 1992;71:206-215.
2. 1 inhibitor: a constellation of syndromes. Mayo Clin Proc. 1989; 64:1269-1275.
3. Nzeako UC, Frigas E. Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161: 2417-2429.
4. 1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol. 1972;1:39-52.
5. 1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N Engl J Med. 1985;312:534-540.
6. Winnewisser J, Ross M, Spath P, Burgi H. Type I hereditary angioedema: variability of clinical presentation and course within two large kindreds. J Intern Med. 1997;241:39-46.
7. Berkun Y, Shalit M. Hereditary angioedema first apparent in the ninth decade during treatment with ACE inhibitor. Ann Allergy Asthma Immunol. 2001;87:138-139.
8. 1-inhibitor deficiency by an angiotensin-converting enzyme inhibitor. Ann Allergy Asthma Immunol. 2001;86:461-464.
9. 1 esterase inhibitor deficiency. Am J Med. 1991;90:278.
10. 1 esterase inhibitor deficiency. J Allergy Clin Immunol. 1997;99:425-426.
11. Scow DT, Smith EG, Schaughnessy A. Combination therapy with ACE inhibitors and angiotensin-receptor blockers in heart failure. Am Fam Physician. 2003;68:1795-1798.
12. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. Arch Intern Med. 1993;153: 2426-2433.
13. Ball SG, Hall AS. Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction. Am Heart J. 1996;132:244-250.
14. Krumholz HM, Vaccarino V, Ellerbeck EF. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons ≥ 65 years of age. Am J Cardiol. 1997;79:581-586.
15. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.
16. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol. 2002;138:99-105.
17. Kostis JB, Kim HJ, Rusak J. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005; 165:1637-1642.
18. Agostoni A, Cicardi M, Cugno M, et al. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology. 1999;44:21-25.
19. Oike Y, Ogata Y, Higashi D, et al. Fatal angioedema associated with enalapril. Intern Med. 1993;32:308-310.
20. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting enzyme inhibition. JAMA. 1988;260:967-970.
21. Shepherd GM. Possible contraindication of angiotensin converting enzyme inhibitors in patients with hereditary angioedema. Am J Med. 1990;88:446.
22. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol. 2002;109:195-209.
23. Nussberger J, Cugno M, Amstutz C. Plasma bradykinin in angioedema. Lancet. 1998;351:1693-1697.
24. Nussberger J, Cugno M, Cicardi M, Agostini A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999;104:1321-1322.
25. 1-inhibitor deficiencies. Blood. 1997;89: 3213-3218.
26. Shoemaker LR, Schurman SJ, Donaldson VH. Hereditary angioneurotic edema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol. 1994; 95:22-28.
27. Curd JG, Prograiss LJ, Cochrane CG. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med. 1980;152:742-747.
28. Schapira M, Silver LD, Scott CF. Prekallikrein activation and high-molecular weight kininogen consumption in hereditary angioedema. N Engl J Med. 1983;308:1050-1053.
29. 2 kinin receptors. Am J Physiol Heart Circ Physiol. 2004;286:H926-H932.
30. Cicardi M, Zingale LC, Bergamaschini L, Agostani A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med. 2004;164:910-913.
31. Cicardi M, Agostani A. Hereditary angioedema. N Engl J Med. 1996;334:1666-1667.
32. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med. 1976;295: 1444-1448.
33. Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol. 1983;72:294-298.
34. Zurlo JJ, Frank MM. The long-term safety of danazol in women with hereditary angioedema. Fertil Steril. 1990;54:64-72.
35. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol. 1997;99:194-196.
36. Cicardi M, Bergamaschini L, Cugno M, Hack E. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol. 1991;87:768-773.
37. Crampon D, Barnou DR, Durand M, et al. Danazol therapy: an unusual aetiology of hepatocellular carcinoma. J Hepatol. 1998; 29:1035-1036.
38. Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenoma in patients taking danazol for hereditary angioedema. Lancet. 1999;353:1066-1067.
39. Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angioedema. J Hepatol. 2002; 36:707-709.
40. 1 activation, plasminogen level and histamine metabolism. Clin Exp Immunol. 1968;3:733-745.
41. Ritchie BC. Protease inhibitors in the treatment of hereditary angioedema. Transfus Apher Sci. 2003;29:259-267.
42. Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med. 1980;302:542-546.
43. Logan RA, Greaves MW. Hereditary angio-oedema: treatment with C1 esterase inhbitor concentrate. J R Soc Med. 1984;77: 1046-1048.
44. Laxenaire MC, Audiberg T, Janot C. Use of purified C1 esterase inhibitor in patients with hereditary angioedema. Anesthesiology. 1990;71:309-311.
45. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion. 1998;38:540-549.
46. Agostoni A, Bergamaschini L, Martignoni G, et al. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy. 1980;44:299-301.
47. Frank MM. Hereditary angioedema. Curr Opin Pediatr. 2005; 17:686-689.
48. Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol. 2005;114:10-16.
49. Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol. 1989;83:677-682.
50. Zuraw BL. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci. 2003; 29:239-245.
51. Nielson EW, Gramstad S. Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand. 2006;50: 120-122.